# A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

> **NCT06213844** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 52 (actual)

## Conditions studied

- Healthy Participants
- Asthma

## Interventions

- **DRUG:** IBI3002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06213844
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-26
- **Primary completion:** 2025-07-22
- **Final completion:** 2025-09-11
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06213844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06213844, "A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06213844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*